Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
-
Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa)
;
Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A. X (Massachusetts General Hospital (Boston)) ;
Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ;
Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
